Kalayda Ganna V, Jansen Bart A J, Wielaard Peter, Tanke Hans J, Reedijk Jan
Gorlaeus Laboratories, Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands.
J Biol Inorg Chem. 2005 May;10(3):305-15. doi: 10.1007/s00775-005-0643-7. Epub 2005 Apr 12.
The biological activity of N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones (aminoalkyl is 2-aminoethyl, 3-aminoprop-1-yl and 4-aminobut-1-yl) and their dinuclear platinum complexes has been evaluated in the U2-OS human osteosarcoma cell line and its cisplatin-resistant U2-OS/Pt subline. All the compounds have been found to exhibit high cytotoxicity in the sensitive cell line, and to overcome cisplatin resistance in U2-OS/Pt cells. Cellular processing of N,N'-bis(2-aminoethyl)-1,4-diaminoanthraquinone and the respective dinuclear platinum complex in the sensitive and resistant U2-OS cells has been studied over time using digital fluorescence microscopy. Cellular processing of the compounds has been found to be similar in sensitive and resistant U2-OS cells, which is in agreement with the lack of cross-resistance in the U2-OS/Pt cell line. Both the platinum complex and the free ligand quickly enter the cell and accumulate in the nucleus. The platinum complex is excreted from the cell via the Golgi apparatus, while the weakly basic anthraquinone ligand accumulates in the Golgi complex, where it is taken up by lysosomes and then transported to the cell surface. The cellular distribution of the fluorescent anthraquinones and their dinuclear platinum complexes in the sensitive/resistant pair of U2-OS osteosarcoma cell lines is compared with the earlier studied cellular processing in the sensitive/resistant pair of A2780 ovarian carcinoma cell lines. In the A2780cisR cell line, the platinum complexes (and not the free ligands) are sequestered in lysosomes, which is not the case in A2780 sensitive cells. The differences in cellular distribution of the compounds in these two sensitive/resistant pairs of cell lines most likely result from different resistance profiles in A2780cisR and U2-OS/Pt cells. Lysosomes of A2780cisR cells are less acidic than lysosomes of A2780 sensitive cells, which is likely to be the cause of a defect in endocytosis. The disruption of normal endocytosis might facilitate sequestration of the platinum complexes in lysosomes, which partly confers the cross-resistance of these complexes with cisplatin in the A2780cisR cell line. In contrast, sequestration in acidic vesicles does not occur in U2-OS/Pt cells that do not exhibit enhanced lysosomal pH and which are likely to have normal endocytosis.
已在U2-OS人骨肉瘤细胞系及其顺铂耐药的U2-OS/Pt亚系中评估了N,N'-双(氨基烷基)-1,4-二氨基蒽醌(氨基烷基为2-氨基乙基、3-氨基丙-1-基和4-氨基丁-1-基)及其双核铂配合物的生物活性。已发现所有化合物在敏感细胞系中均表现出高细胞毒性,并能克服U2-OS/Pt细胞中的顺铂耐药性。使用数字荧光显微镜对敏感和耐药的U2-OS细胞中N,N'-双(2-氨基乙基)-1,4-二氨基蒽醌及其相应的双核铂配合物随时间的细胞处理情况进行了研究。已发现化合物在敏感和耐药的U2-OS细胞中的细胞处理情况相似,这与U2-OS/Pt细胞系中缺乏交叉耐药性一致。铂配合物和游离配体均迅速进入细胞并在细胞核中积累。铂配合物通过高尔基体从细胞中排出,而弱碱性蒽醌配体则在高尔基体复合物中积累,在那里它被溶酶体摄取,然后转运到细胞表面。将荧光蒽醌及其双核铂配合物在敏感/耐药的U2-OS骨肉瘤细胞系对中的细胞分布与早期研究的敏感/耐药的A2780卵巢癌细胞系对中的细胞处理情况进行了比较。在A2780cisR细胞系中,铂配合物(而非游离配体)被隔离在溶酶体中,而在A2780敏感细胞中则不然。这两个敏感/耐药细胞系对中化合物细胞分布的差异很可能是由于A2780cisR和U2-OS/Pt细胞中不同的耐药谱所致。A2780cisR细胞的溶酶体酸性低于A2780敏感细胞的溶酶体,这可能是内吞作用缺陷的原因。正常内吞作用的破坏可能有助于铂配合物在溶酶体中的隔离,这部分赋予了这些配合物在A2780cisR细胞系中与顺铂的交叉耐药性。相比之下,在不表现出溶酶体pH升高且可能具有正常内吞作用的U2-OS/Pt细胞中,不会发生在酸性囊泡中的隔离。